He discusses his session titled “The Microbiome and Fatty Liver Disease,” which he presented at Harvard’s Nonalcoholic Fatty Liver Disease (NAFLD): Mechanisms and Novel Therapeutics symposium.
Neurology Consultant Advisory Board Member Anamaria Shanley, MSN, APRN-C, discusses the impact of the COVID-19 pandemic, social distancing, and the transition to telemedicine on the older adults she sees in...
In this video, David Conen, MD, MPH, provides insight into the results of the Swiss Atrial Fibrillation Cohort (Swiss-AF) trial and what they reveal about the incidence of clinically silent brain infarcts...
